Abstract
Original language | English |
---|---|
Pages (from-to) | 1651-1664 |
Number of pages | 14 |
Journal | Nature Genetics |
Volume | 55 |
Issue number | 10 |
Early online date | 2023 |
DOIs | |
Publication status | Published - Oct 2023 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature Genetics, Vol. 55, No. 10, 10.2023, p. 1651-1664.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification
AU - Kavousi, Maryam
AU - Bos, Maxime M.
AU - Barnes, Hanna J.
AU - Cardenas, Christian L. Lino
AU - Wong, Doris
AU - Lu, Haojie
AU - Hodonsky, Chani J.
AU - Landsmeer, Lennart P. L.
AU - Turner, Adam W.
AU - Kho, Minjung
AU - Hasbani, Natalie R.
AU - de Vries, Paul S.
AU - Bowden, Donald W.
AU - Chopade, Sandesh
AU - Deelen, Joris
AU - Benavente, Ernest Diez
AU - Guo, Xiuqing
AU - Hofer, Edith
AU - Hwang, Shih-Jen
AU - Lutz, Sharon M.
AU - Lyytikäinen, Leo-Pekka
AU - Slenders, Lotte
AU - Smith, Albert V.
AU - Stanislawski, Maggie A.
AU - van Setten, Jessica
AU - Wong, Quenna
AU - Yanek, Lisa R.
AU - Becker, Diane M.
AU - Beekman, Marian
AU - Budoff, Matthew J.
AU - Feitosa, Mary F.
AU - Finan, Chris
AU - Hilliard, Austin T.
AU - Kardia, Sharon L. R.
AU - Kovacic, Jason C.
AU - Kral, Brian G.
AU - Langefeld, Carl D.
AU - Launer, Lenore J.
AU - Malik, Shaista
AU - Hoesein, Firdaus A. A. Mohamed
AU - Mokry, Michal
AU - Schmidt, Reinhold
AU - Smith, Jennifer A.
AU - Taylor, Kent D.
AU - Terry, James G.
AU - van der Grond, Jeroen
AU - van Meurs, Joyce
AU - Vliegenthart, Rozemarijn
AU - Xu, Jianzhao
AU - Young, Kendra A.
AU - Zilhão, Nuno R.
AU - Zweiker, Robert
AU - Assimes, Themistocles L.
AU - Becker, Lewis C.
AU - Bos, Daniel
AU - Carr, J. Jeffrey
AU - Cupples, L. Adrienne
AU - de Kleijn, Dominique P. v.
AU - de Winther, Menno
AU - den Ruijter, Hester M.
AU - Fornage, Myriam
AU - Freedman, Barry I.
AU - Gudnason, Vilmundur
AU - Hingorani, Aroon D.
AU - Hokanson, John E.
AU - Ikram, M. Arfan
AU - Išgum, Ivana
AU - Jacobs, David R.
AU - Kähönen, Mika
AU - Lange, Leslie A.
AU - Lehtimäki, Terho
AU - Pasterkamp, Gerard
AU - Raitakari, Olli T.
AU - Schmidt, Helena
AU - Slagboom, P. Eline
AU - Uitterlinden, André G.
AU - Vernooij, Meike W.
AU - Bis, Joshua C.
AU - Franceschini, Nora
AU - Psaty, Bruce M.
AU - Post, Wendy S.
AU - Rotter, Jerome I.
AU - Björkegren, Johan L. M.
AU - O’Donnell, Christopher J.
AU - Bielak, Lawrence F.
AU - Peyser, Patricia A.
AU - Malhotra, Rajeev
AU - van der Laan, Sander W.
AU - Miller, Clint L.
N1 - Funding Information: This work was supported by grants from the National Institutes of Health (R01HL148239 and R01HL164577 to C.L.M.; R01HL142809 and R01HL159514 to R.M.; F31HL156463 to D.W.; R01HL125863 to J.L.M.B.; R01HL146860 to P.S.d.V., K01HL164687 to C.L.L.C., N.R.H., P.A.P. and L.F.B.; R01HL163972 to N.F.; P30DK063491 to J.I.R.; R01DK114183 to T.L.A.; European Union funded H2020 TO_AITION (grant 848146 to S.W.v.d.L.); Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation (CVON 2011/B019 and CVON 2017-20 (to S.W.v.d.L. and M.d.W.)—generating the best evidence-based pharmaceutical targets for atherosclerosis (GENIUS I&II)), the ERA-CVD program ‘druggable-MI-targets’ (01KL1802 to S.W.v.d.L.) and the Leducq Foundation (‘PlaqOmics’ 18CVD02 to C.L.M., J.L.M.B., G.P. and S.W.v.d.L.). The CHARGE Consortium was supported by NHLBI (grant R01HL105756). M.d.W. was supported by the Netherlands Heart Foundation and Spark-Holding BV (2019B016); Leducq Foundation (LEAN 16CVD01); Amsterdam UMC; ZonMW (Open Competition 09120011910025). A full list of the funding support for each study is provided in . A full list of acknowledged funding support for individual studies is provided in Supplementary Table . Funding Information: S.W.v.d.L. has received Roche funding for unrelated work. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. R.M. receives research funding from Angea Biotherapeutics and Amgen and serves as a consultant for Myokardia/BMS, Renovacor, Epizon Pharma and Third Pole, all unrelated to the current project. C.L.M. has received funding from AstraZeneca on an unrelated project. J.C.K. is the recipient of an Agilent Thought Leader Award (January 2022), which includes funding for research that is unrelated to the current paper. The other authors declare no competing interests. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2023/10
Y1 - 2023/10
N2 - Coronary artery calcification (CAC), a measure of subclinical atherosclerosis, predicts future symptomatic coronary artery disease (CAD). Identifying genetic risk factors for CAC may point to new therapeutic avenues for prevention. Currently, there are only four known risk loci for CAC identified from genome-wide association studies (GWAS) in the general population. Here we conducted the largest multi-ancestry GWAS meta-analysis of CAC to date, which comprised 26,909 individuals of European ancestry and 8,867 individuals of African ancestry. We identified 11 independent risk loci, of which eight were new for CAC and five had not been reported for CAD. These new CAC loci are related to bone mineralization, phosphate catabolism and hormone metabolic pathways. Several new loci harbor candidate causal genes supported by multiple lines of functional evidence and are regulators of smooth muscle cell-mediated calcification ex vivo and in vitro. Together, these findings help refine the genetic architecture of CAC and extend our understanding of the biological and potential druggable pathways underlying CAC.
AB - Coronary artery calcification (CAC), a measure of subclinical atherosclerosis, predicts future symptomatic coronary artery disease (CAD). Identifying genetic risk factors for CAC may point to new therapeutic avenues for prevention. Currently, there are only four known risk loci for CAC identified from genome-wide association studies (GWAS) in the general population. Here we conducted the largest multi-ancestry GWAS meta-analysis of CAC to date, which comprised 26,909 individuals of European ancestry and 8,867 individuals of African ancestry. We identified 11 independent risk loci, of which eight were new for CAC and five had not been reported for CAD. These new CAC loci are related to bone mineralization, phosphate catabolism and hormone metabolic pathways. Several new loci harbor candidate causal genes supported by multiple lines of functional evidence and are regulators of smooth muscle cell-mediated calcification ex vivo and in vitro. Together, these findings help refine the genetic architecture of CAC and extend our understanding of the biological and potential druggable pathways underlying CAC.
UR - http://www.scopus.com/inward/record.url?scp=85172796432&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41588-023-01518-4
DO - https://doi.org/10.1038/s41588-023-01518-4
M3 - Article
C2 - 37770635
SN - 1061-4036
VL - 55
SP - 1651
EP - 1664
JO - Nature Genetics
JF - Nature Genetics
IS - 10
ER -